Translated title of the contribution: Antileukotrienes in asthma

P. H.M. Van Der Kuy*, J-W.J. Lammers

*Corresponding author for this work

Research output: Contribution to journalReview articlePopular

1 Citation (Scopus)


Several new drugs are now under development for the treatment of asthma, amongst them are anti-leukotrienes. This group consists of both leukotriene receptor antagonists and leukotriene synthesis inhibitors. The leukotrienes (LT) B 4, C 4, D 4 and E 4 are metabolites of arachidonic acid. LTC 4, LTD 4 and LTE 4 were metabolites of arachidonic acid. LTC 4, LTD 4 and LTE 4 were formerly known as the Slow Reacting Substance of Anaphylaxis (SRS-A). These mediators are implicated in the pathophysiology of asthma due to exercise, allergen inhalation and acetylsalicylic acid use. The main effect of LTB 4 is neutrophil chemotaxis. LTC 4, LTD 4 and LTE 4 are associated with bronchus obstruction. A review of the results of various clinical studies with these new compounds is presented. The review is limited to asthma due to allergen inhalation, exercise induced asthma and acetylsalicylic acid induced asthma. Finally the reported adverse reactions and possible contraindications are discussed.

Translated title of the contributionAntileukotrienes in asthma
Original languageDutch
Pages (from-to)495-504
Number of pages10
JournalPharmaceutisch Weekblad
Issue number17
Publication statusPublished - 1996
Externally publishedYes


Dive into the research topics of 'Antileukotrienes in asthma'. Together they form a unique fingerprint.

Cite this